Antitumor pharmacological research in the era of personalized medicine

被引:1
作者
Huang, Min [1 ,2 ]
Geng, Mei-yu [1 ,2 ]
Ding, Jian [1 ,2 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[2] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
基金
中国国家自然科学基金;
关键词
personalized medicine; anticancer drug discovery; oncogene addiction; non-oncogene addiction; combination therapy; THERAPEUTIC RESPONSE; ANTICANCER THERAPY; CANCER-THERAPY; INHIBITORS; FGFR; BIOMARKERS; ADDICTION; ONCOGENE;
D O I
10.1038/s41401-022-01023-0
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Anticancer drug discovery has yielded unprecedented progress in recent decades, resulting in the approval of innovative treatment options for patients and the successful implementation of personalized medicine in clinical practice. This remarkable progress has also reshaped the research scope of pharmacological research. This article, as a tribute to cancer research at Shanghai Institute of Materia Medica in celebration of the institute's 90th birthday, provides an overview of the conceptual revolution occurring in anticancer therapy, and summarizes our recent progress in the development of molecularly targeted therapeutics and exploration of new strategies in personalized medicine. With this review, we hope to provide a glimpse into how antitumor pharmacological researchers have embraced the new era of personalized medicine research and to propose a future path for anticancer drug discovery and pharmacological research.
引用
收藏
页码:3015 / 3020
页数:6
相关论文
共 46 条
  • [1] Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models
    Ai, Jing
    Chen, Yi
    Peng, Xia
    Ji, Yinchun
    Xi, Yong
    Shen, Yanyan
    Yang, Xinying
    Su, Yi
    Sun, Yiming
    Gao, Yinglei
    Ma, Yuchi
    Xiong, Bing
    Shen, Jingkang
    Ding, Jian
    Geng, Meiyu
    [J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (04) : 751 - 762
  • [2] Integrating predictive biomarkers and classifiers into oncology clinical development programmes
    Beckman, Robert A.
    Clark, Jason
    Chen, Cong
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (10) : 735 - 748
  • [3] The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
    Canon, Jude
    Rex, Karen
    Saiki, Anne Y.
    Mohr, Christopher
    Cooke, Keegan
    Bagal, Dhanashri
    Gaida, Kevin
    Holt, Tyler
    Knutson, Charles G.
    Koppada, Neelima
    Lanman, Brian A.
    Werner, Jonathan
    Rapaport, Aaron S.
    San Miguel, Tisha
    Ortiz, Roberto
    Osgood, Tao
    Sun, Ji-Rong
    Zhu, Xiaochun
    McCarter, John D.
    Volak, Laurie P.
    Houk, Brett E.
    Fakih, Marwan G.
    O'Neil, Bert H.
    Price, Timothy J.
    Falchook, Gerald S.
    Desai, Jayesh
    Kuo, James
    Govindan, Ramaswamy
    Hong, David S.
    Ouyang, Wenjun
    Henary, Haby
    Arvedson, Tara
    Cee, Victor J.
    Lipford, J. Russell
    [J]. NATURE, 2019, 575 (7781) : 217 - +
  • [4] Chen XX, 2022, CANCER RES, V82
  • [5] Kinase drug discovery 20 years after imatinib: progress and future directions
    Cohen, Philip
    Cross, Darren
    Janne, Pasi A.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (07) : 551 - 569
  • [6] Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
    Dang, Lenny
    White, David W.
    Gross, Stefan
    Bennett, Bryson D.
    Bittinger, Mark A.
    Driggers, Edward M.
    Fantin, Valeria R.
    Jang, Hyun Gyung
    Jin, Shengfang
    Keenan, Marie C.
    Marks, Kevin M.
    Prins, Robert M.
    Ward, Patrick S.
    Yen, Katharine E.
    Liau, Linda M.
    Rabinowitz, Joshua D.
    Cantley, Lewis C.
    Thompson, Craig B.
    Heiden, Matthew G. Vander
    Su, Shinsan M.
    [J]. NATURE, 2009, 462 (7274) : 739 - U52
  • [7] Multiple targeted tyrosine kinase inhibition in the clinic: All for one or one for all?
    de Jonge, M. J. A.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (10) : 1351 - 1356
  • [8] Clinical Challenges of Immune Checkpoint Inhibitors
    de Miguel, Maria
    Calvo, Emiliano
    [J]. CANCER CELL, 2020, 38 (03) : 326 - 333
  • [9] Dienstmann R, 2012, ANN ONCOL, V23, P116
  • [10] Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
    DiNardo, C. D.
    Stein, E. M.
    de Botton, S.
    Roboz, G. J.
    Altman, J. K.
    Mims, A. S.
    Swords, R.
    Collins, R. H.
    Mannis, G. N.
    Pollyea, D. A.
    Donnellan, W.
    Fathi, A. T.
    Pigneux, A.
    Erba, H. P.
    Prince, G. T.
    Stein, A. S.
    Uy, G. L.
    Foran, J. M.
    Traer, E.
    Stuart, R. K.
    Arellano, M. L.
    Slack, J. L.
    Sekeres, M. A.
    Willekens, C.
    Choe, S.
    Wang, H.
    Zhang, V.
    Yen, K. E.
    Kapsalis, S. M.
    Yang, H.
    Dai, D.
    Fan, B.
    Goldwasser, M.
    Liu, H.
    Agresta, S.
    Wu, B.
    Attar, E. C.
    Tallman, M. S.
    Stone, R. M.
    Kantarjian, H. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) : 2386 - 2398